exon 52

Dutch biotechnology company Prosensa and multinational pharmaceutical company GlaxoSmithKline are moving ahead with plans to test drugs targeting several exons in the dystrophin gene

posted on October 29, 2012 - 5:00am
Update (Feb. 1, 2013): Dutch biopharmaceutical company Prosensa announced Jan. 29 that it has received orphan drug status in the United States and the European Union for compounds in development for the treatment of Duchenne muscular dystrophy.

Investigators are testing compounds designed to cause exon skipping in Duchenne MD and drugs that may increase blood flow in Duchenne and Becker MD

posted on June 21, 2011 - 9:08am
U.S. trial of eteplirsen for Duchenne MD delayed